| |
Learn de-risking strategies in our whitepaper and explore the future of precision treatments from our survey of 100+ oncology professionals.
|
|
Today’s Big NewsOct 15, 2024 |
|
Gene and cellular therapies hold the extraordinary potential to transform
global health care. Download the QPS White Paper to explore the 5 critical
criteria to consider when choosing the best CRO for your next cell and gene
therapy development program.
|
|
| By Gabrielle Masson Johnson & Johnson is jettisoning several programs, with three of the culls taking place in the neuroscience field. |
|
|
|
By Zoey Becker The company picked up a record $3 billion in quarterly sales for its multiple myeloma powerhouse Darzalex as it grooms Tremfya to take on Stelara's market dominance. |
By Fraiser Kansteiner Pfizer is laying out $49 million up front in a partnership and licensing pact with Massachusetts-based Triana Biomedicines to discover molecular glue degraders for cancer and other conditions. The deal could ultimately be worth more than $1.5 billion, thanks to potential royalties and milestones. |
By Conor Hale TORONTO—Digital health regulators from the FDA and Health Canada, as well as leaders from the medtech industry, discussed how they will keep up with the speed of AI at the AdvaMed MedTech Conference in Toronto. |
|
Wednesday, October 23, 2024 | 11am ET / 8am PT Large, deeply characterized patient cohorts are one of the most promising data resources today for understanding disease biology and developing new medicines. Join us as we explore how this data is driving the next generation of pharmaceutical development. Learn how to leverage genetic research in today's highly competitive landscape. Register now.
|
|
By Angus Liu Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it could prolong patients’ lives in extensive-stage small cell lung cancer. |
By Andrea Park A new campaign kicking off during October’s Breast Cancer Awareness Month is aimed at raising awareness of the health disparities facing Black breast cancer patients and providing care tailored to their specific needs. |
By Darren Incorvaia Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) and body weight in a phase 2 trial of patients with type 2 diabetes, the company announced in an Oct. 15 release. |
By Nick Paul Taylor Otsuka has quantified the financial impact of caregivers, calculating that people in the U.S. who look after loved ones with dementia would earn $114,000 on average if paid for the daily care they provide. |
By Gabrielle Masson Cell therapy biotech Tolerance Bio has unveiled with $17.2 million and a mission of targeting immune diseases by stretching and saving the function of a key organ. |
By Joseph Keenan Baxter International, which was forced by flooding from Hurricane Helene to temporarily halt production at its North Carolina facility, has started importing intravenous fluids from foreign facilities to help alleviate a U.S. shortage of essential medical supplies. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Pharma's Fraiser Kansteiner chats with industry leaders about the surge in neuroscience investment, breakthroughs and future targets in neuropharmaceuticals. |
|
|---|
|
|
|
Thursday, October 24, 2024 | 1pm ET / 10am PT We will explore how incorporating comprehensive genetic services, like genetic testing access programs and clinical trial matching services, can increase identification of patients who meet program-specific inclusion/exclusion criteria, helping more patients benefit from life-changing therapeutics. Register today!
|
|
| eBookNeed the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
| WhitepaperTake a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
| WhitepaperUnlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
| WhitepaperFinding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
